Insulin detemir har jämförts med NPH-insulin. Behandlingsstudier visar inga egentliga skillnader
Research output: Contribution to journal › Article
To investigate the evidence behind supposed advantages of insulin detemir over existing therapy (NPH insulin), we carried out a systematic review. We analysed the available documentation presented after registration of the drug by the European drug regulatory authority (EMEA) and approached the data presented at the authority's Internet site. Some data from Food and Drug Administraion (FDA) contributed. All published studies not included in the registration file were also included in the analysis. Data on glycaemic control, expressed as HbA1c, hypoglycaemia, and change in body weight were registered. Quality of life - a secondary endpoint infrequently investigated - was considered. All studies included a comparison with NPH insulin, incorporating both type 1 and type 2-diabetes. There was no consistent difference between the two insulin treatments regarding HbA1c, nor was there any evidence concerning differences regarding hypoglycaemia, except instances of mild nocturnal hypoglycaemia. These cases were not adequately reported, however. A small change in body weight in favour of insulin detemir was detected. No data on quality of life was identified.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Publication status||Published - 2006|
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Psychiatry/Primary Care/Public Health (013240500)